Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib

- Prediabetes and diabetes represent adverse events in patients with chronic myeloid leukemia treated with nilotinib.
- An unweighted genetic risk score <10 predicts higher prediabetes/diabetes-free survival after nilotinib treatment.
- In clinical practice, the unweighted genetic risk score uGRS helps tailor the best tyrosine kinase inhibitor therapy.